Will Life Sciences Firms Fall Off the Fiscal Cliff?
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Jeremy Glaser: For Morningstar, I'm Jeremy Glaser.
We're over a year from the debt ceiling debate, and some of the budget cuts are now planned to happen in January. One industry where this is looming large is life sciences. I'm here with Alex Morozov; he is the director of health-care research at Morningstar. We're going to take a look at the industry and see if there is still any value there.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.